 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 November 2003 | Volume 139 Issue 9 | Pages 777-780
The recent Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed that the primary end point, coronary heart disease, was identical in the chlorthalidone, lisinopril, and amlodipine groups. Yet the major conclusion of this trial was that thiazide diuretics are superior in preventing 1 or more major forms of cardiovascular disease and should be preferred for first-line antihypertensive therapy. This conclusion was based solely on an analysis of secondary end points and cost. As evidenced by the dictum to "use thiazides for most patients with uncomplicated hypertension" in the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, this interpretation of ALLHAT broadly adumbrated these guidelines. Although diuretics will rightfully remain a cornerstone in antihypertensive therapy, we should remember (as we were told by the ALLHAT investigators) that secondary end points are "soft data" that should not form a basis for main conclusions or lead to a labeling of a drug class as preferred.
Author and Article Information
From Ochsner Clinic Foundation, New Orleans, Louisiana.
Potential Financial Conflicts of Interest:Honoraria and grant support: Abbott Laboratories, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Forest Pharmaceuticals, GlaxoSmithKline, Integrium, Knoll Pharmaceuticals, Merck & Co., Novartis, Pfizer, Procter & Gamble, Recordati, Reliant Pharmaceuticals, Roche, Sankyo, Searle, Solvay Pharmaceuticals, Wyeth; Expert testimony: Procter & Gamble.
Current Author Address: Franz H. Messerli, MD, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121; e-mail, fmesserli{at}aol.com. PERSPECTIVE
ALLHAT, or the Soft Science of the Secondary End Point
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  F. H. Messerli and J. A. Staessen Amlodipine Better Than Lisinopril?: How One Randomized Clinical Trial Ended Fallacies From Observational Studies Hypertension, September 1, 2006; 48(3): 359 - 361. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Kotchen From Clinical Trials to Clinical Practice: Why the Gap? Hypertension, August 1, 2006; 48(2): 196 - 197. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Zillich, J. Garg, S. Basu, G. L. Bakris, and B. L. Carter Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review Hypertension, August 1, 2006; 48(2): 219 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H.H. Leenen ALLHAT: What has it taught us so far? Can. Med. Assoc. J., September 28, 2004; 171(7): 719 - 720. [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Davis, C. D. Furberg, J. T. Wright Jr., J. A. Cutler, P. Whelton, and the ALLHAT Collaborative Research Group ALLHAT: Setting the Record Straight Ann Intern Med, July 6, 2004; 141(1): 39 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Editors Publishing Commentary by Authors with Potential Conflicts of Interest: When, Why, and How Ann Intern Med, July 6, 2004; 141(1): 73 - 74. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Neely ALLHAT, or the Soft Science of the Secondary End Point Ann Intern Med, July 6, 2004; 141(1): 77 - 77. [Full Text] [PDF]
|
|
|
|
|
|
A. Ahmed Impact of ALLHAT on the Role of Angiotensin-Converting Enzyme Inhibitors in the Primary Prevention of Heart Failure Ann Intern Med, July 6, 2004; 141(1): W-9 - W-9. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Pijak, F. Gazdik, and S. Hrusovsky The best type of trial Can. Med. Assoc. J., June 8, 2004; 170(12): 1772 - 1773. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Iadecola and P. B. Gorelick Hypertension, Angiotensin, and Stroke: Beyond Blood Pressure Stroke, February 1, 2004; 35(2): 348 - 350. [Full Text] [PDF]
|
|
Article
